AR034585A1 - Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos - Google Patents

Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos

Info

Publication number
AR034585A1
AR034585A1 ARP020101168A ARP020101168A AR034585A1 AR 034585 A1 AR034585 A1 AR 034585A1 AR P020101168 A ARP020101168 A AR P020101168A AR P020101168 A ARP020101168 A AR P020101168A AR 034585 A1 AR034585 A1 AR 034585A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
compounds
heteroarylalkyl
arylalkyl
Prior art date
Application number
ARP020101168A
Other languages
English (en)
Inventor
Spencer David Kimball
Louis J Lombardo
David B Rawlins
Hai-Yun Xiao
Robert Joseph Schmidt
David Kent Williams
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR034585A1 publication Critical patent/AR034585A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula (1) sus enantiómeros, diastereómeros, sales farmacéuticamente aceptables, profármacos y solvatos de los mismos caracterizado porque: R1 se selecciona del grupo que consiste de hidrógeno, alquilo y cicloalquilo; R2 y R3 son cada uno independientemente seleccionados del grupo que consiste de H, alquilo, arilo, heteroarilo, arilalquilo, cicloalquilo, heterocicloalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo; o R2 y R3 pueden también ser tomados en conjunto para formar un anillo heterocíclico o carbocíclico; R4 se selecciona del grupo que consiste de alquilo, arilalquilo, cicloalquilalquilo, heteroarilalquilo, heterocicloalquilo, aminoalquilo, heterocicloalquilalquilo, CN, C(O)R5, CO2R5 y CONR5R6; R5 y R6 son cada uno independientemente seleccionados del grupo que consiste de H, alquilo, cicloalquilo, hidroxialquilo, alquenilo, alcoxi, tioalcoxi, alcoxialquilo, haloalquilo, arilo, heteroarilo, arilalquilo, cicloalquilalquilo, heteroarilalquilo y heterocicloalquilalquilo, o N-R5R6 juntos forman un heterocicloalquilo; Z se selecciona del grupo que consiste de O, S y NR8; R8 se selecciona del grupo que consiste de H, CN, sulfoamido, OR7, alquilo, cicloalquilo, arilo, arilalquilo, heterociclilo, heteroarilo y heteroarilalquilo; y R7 se selecciona del grupo que consiste de H, alquilo, arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo, Los compuestos de fórmula (1) inducen interrupción mitótica haciéndolos con ello útiles como agentes anticancerígenos. Los compuestos de fórmula (1) son también empleados para el tratamiento de otros padecimientos, los cuales pueden ser tratados induciendo interrupción mitótica. Composición farmacéutica y procedimientos para preparar los compuestos de fórmula (1) y los intermediarios.
ARP020101168A 2001-03-29 2002-03-27 Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos AR034585A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27995601P 2001-03-29 2001-03-29

Publications (1)

Publication Number Publication Date
AR034585A1 true AR034585A1 (es) 2004-03-03

Family

ID=23071059

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101168A AR034585A1 (es) 2001-03-29 2002-03-27 Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos

Country Status (26)

Country Link
US (1) US6809102B2 (es)
EP (1) EP1373221A4 (es)
JP (1) JP2005504725A (es)
KR (1) KR20030086327A (es)
CN (1) CN1507435A (es)
AR (1) AR034585A1 (es)
BG (1) BG108180A (es)
BR (1) BR0208405A (es)
CA (1) CA2442482A1 (es)
CZ (1) CZ20032645A3 (es)
EE (1) EE200300474A (es)
HR (1) HRP20030875A2 (es)
HU (1) HUP0400350A3 (es)
IL (1) IL157441A0 (es)
IS (1) IS6967A (es)
MX (1) MXPA03008634A (es)
NO (1) NO20034300L (es)
PE (1) PE20021013A1 (es)
PL (1) PL373759A1 (es)
RU (1) RU2003130961A (es)
SK (1) SK11062003A3 (es)
TW (1) TWI228416B (es)
UY (1) UY27232A1 (es)
WO (1) WO2002079149A2 (es)
YU (1) YU75803A (es)
ZA (2) ZA200306648B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900214B2 (en) * 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
EP1847534B9 (en) * 2001-12-11 2012-03-21 Kyowa Hakko Kirin Co., Ltd. Thiadiazoline derivatives for treating cancer
DK1601673T3 (da) * 2003-03-07 2009-08-24 Astrazeneca Ab Kondenserede heterocykler og anvendelser af disse
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
EP1616866B1 (en) 2003-04-18 2011-12-14 Kyowa Hakko Kirin Co., Ltd. M-stage kinesin inhibitor
AU2004247551A1 (en) * 2003-06-10 2004-12-23 Fuji Photo Film Co., Ltd. Thiadiazoline derivative
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
US20050282838A1 (en) * 2003-10-16 2005-12-22 Shyamlal Ramchandani Compounds, compositions, and methods
BRPI0513513A (pt) * 2004-07-22 2008-05-06 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
MX2007001953A (es) * 2004-08-18 2007-05-09 Astrazeneca Ab Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
JPWO2006101103A1 (ja) * 2005-03-22 2008-09-04 協和醗酵工業株式会社 造血器腫瘍治療剤
KR20070113300A (ko) * 2005-03-22 2007-11-28 교와 핫꼬 고교 가부시끼가이샤 고형종양 치료제
WO2006137490A1 (ja) * 2005-06-24 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 再狭窄治療剤
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
CN110464722B (zh) * 2019-06-06 2023-05-23 暨南大学 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211198B1 (en) 1993-04-05 2001-04-03 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
SK60097A3 (en) 1994-11-16 1998-01-14 Synaptic Pharma Corp Dihydropyrimidines, pharmaceutical composition containing same and use thereof
WO1997017969A1 (en) 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
EP1021185A4 (en) 1996-05-16 2005-09-07 Synaptic Pharma Corp DIHYDROPYRIMIDINE AND ITS USES.
US6080760A (en) 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
WO1998057639A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. ALPHA 1aADRENERGIC RECEPTOR ANTAGONISTS
WO1999025345A1 (en) 1997-11-14 1999-05-27 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
US6346389B1 (en) 1998-04-01 2002-02-12 Yale University Method for selectively modulating the interactions between survivin and tubulin
US6300084B1 (en) 1998-10-08 2001-10-09 The Regents Of The University Of California Anti-mitotic agent screening process
AUPQ171999A0 (en) 1999-07-20 1999-08-12 University Of Sydney, The Neurotropic virus transport
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
EP1226129B1 (en) 1999-10-27 2006-05-24 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6284480B1 (en) 2000-04-03 2001-09-04 Cytokinetics, Inc. Antifungal assay
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Also Published As

Publication number Publication date
KR20030086327A (ko) 2003-11-07
HUP0400350A2 (hu) 2005-01-28
CZ20032645A3 (cs) 2004-06-16
JP2005504725A (ja) 2005-02-17
BR0208405A (pt) 2004-03-30
HRP20030875A2 (en) 2004-08-31
MXPA03008634A (es) 2003-12-08
IS6967A (is) 2003-09-24
YU75803A (sh) 2006-05-25
US20030008888A1 (en) 2003-01-09
WO2002079149A2 (en) 2002-10-10
CA2442482A1 (en) 2002-10-10
RU2003130961A (ru) 2005-04-10
PE20021013A1 (es) 2002-11-10
HUP0400350A3 (en) 2005-06-28
NO20034300D0 (no) 2003-09-26
BG108180A (en) 2004-09-30
EP1373221A4 (en) 2004-09-29
WO2002079149A3 (en) 2003-02-27
UY27232A1 (es) 2002-11-29
PL373759A1 (en) 2005-09-05
NO20034300L (no) 2003-11-07
SK11062003A3 (sk) 2004-08-03
EP1373221A2 (en) 2004-01-02
ZA200307320B (en) 2004-12-20
ZA200306648B (en) 2004-11-26
CN1507435A (zh) 2004-06-23
EE200300474A (et) 2003-12-15
IL157441A0 (en) 2004-03-28
TWI228416B (en) 2005-03-01
US6809102B2 (en) 2004-10-26

Similar Documents

Publication Publication Date Title
AR034585A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR036659A1 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR077267A1 (es) Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
AR036107A1 (es) Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
AR035777A1 (es) Derivados de pirazol sustituidos, procesos para su preparacion, composiciones farmaceuticas que los contienen, y su uso en medicina
EA200600364A1 (ru) Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора
AR038341A1 (es) Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l
WO2006046031A8 (en) Pharmaceutical compounds
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
AR072545A1 (es) Fenilpirazinonas como inhibidores de la btk, composicion farmaceutica que las contiene y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades autoinmunes e inflamatorias.
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
EA200701640A1 (ru) Новые соединения с терапевтическим эффектом
PE20060483A1 (es) Compuestos heterociclicos como antagonistas de nk1
AR057296A1 (es) Diarilsulfona sulfonamidas y el uso de las mismas
PE20020735A1 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
AR047958A1 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central.

Legal Events

Date Code Title Description
FB Suspension of granting procedure